This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tiny Biotechs Dancing in the Bull Pen

A speculative fervor has gripped small-cap biotech stocks.

They're up, in some cases big. Tiny, high-risk biotech companies suffered crushing declines in the price of their shares last year. But today, investors (or perhaps just traders) are embracing many of these stocks.

OncoGenex Pharmaceuticals (OGXI - Get Report) has gone from $4 to more than $13 in the last month. Hemispherx BioPharma (HEB - Get Report) is up more than 50% since the beginning of May. Shares of Novogen (NVGN) more doubled this week alone.

Biocryst Pharmaceuticals (BCRX - Get Report), Emisphere Technologies (EMIS) and Immunomedics (IMMU - Get Report) are all also strongly higher in the past month.

It's hard to pinpoint one reason for the embrace of the small in the biotech sector, but the confluence of a few disparate events seemed to have put investors in a risk-taking mood.

First, the outbreak of the H1N1 virus sent investors looking for antiviral-related drug stocks. And, of course, many of these companies obliged by issuing press releases designed to highlight their influenza drug programs.

Then came the surprising approval of Vanda Pharmaceutical's (VNDA - Get Report) schizophrenia drug Fanapt, which sent the once penny stock soaring 900%.

Last, the release of research abstracts for the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) had investors scouring new breakthrough cancer treatments regardless of their odds for success.

Dan Rosenblum, a biotech trader and author of the Shark Biotech investment newsletter, believes traders and momentum investors are scouring biotech for the next Vanda.

"When people saw a penny stock like Vanda could move up 1000%, that created excitement for the next one. Traders are looking for the next Vanda, or at least they're hyping some of these stocks in the hope that someone believes they're the next Vanda," he says.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
EMIS $0.66 -0.41%
BCRX $3.43 5.21%
HEB $0.14 -0.51%
IMMU $3.68 3.66%
OGXI $0.91 -6.66%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs